Background: This study compared the efficacy of transdermally administered estradiol with that of orally administered conjugated equine estrogens (CEE) on the renin-angiotensin system, plasma bradykinin level, and blood pressure (BP) in normotensive postmenopausal women (PMW).
T he renin-angiotensin system plays a critical role in the regulation of blood pressure (BP) and in the pathophysiology of hypertension. Oral hormone replacement therapy (HRT) dose-dependently increases renin substrate, which is the same as angiotensinogen, but transdermal HRT usually does not affect angiotensinogen levels. [1] [2] [3] Plasma renin activity (PRA) has been found to be either unchanged or increased in women who receive either oral or transdermal HRT. 4 -7 Oral HRT reduces the activity of angiotensin-converting enzyme (ACE) in postmenopausal women, whereas transdermal HRT has little effect. 2,4,8 -11 Generally, the reduction in ACE activity would be expected to reduce the plasma angiotensin (Ang) II levels and to increase the Ang I and bradykinin levels. In fact, however, the plasma Ang I levels were either unchanged or increased by oral HRT, whereas the plasma Ang II levels were increased. 4 The bradykinin levels increased concomitantly as ACE activity decreased in the women who received oral HRT. 4, 5, 9, 10 However, whether transdermal HRT, like oral HRT, affects circulating levels of Ang I, Ang II, and bradykinin in postmenopausal women has not been investigated.
In contrast to oral HRT, transdermal HRT has been reported to have little effect on serum lipids, lipoprotein, and fibrinolysis 12, 13 and to have no adverse effects on coagulation, renin substrate, or triglyceride levels. 12, 14 Af-ter oral administration, most estrogens reach the liver via the portal circulation and are metabolized through a process called the first-pass effect. The result is nonphysiologic levels of estrone, estrone sulfate, and various hepatic proteins such as renin substrate, sex-hormone-binding globulin, thyroxine-binding globulin, and cortisol-binding gloublin.
As parenteral estradiol administration avoids hepatic metabolism, it may prevent some of the undesired effects of oral treatment and be more suitable for HRT. 15, 16 It therefore seemed important to investigate the physiologic effects of estrogen administered by both transdermal and oral routes.
This study was designed to compare the effects of transdermal and oral HRT on components of the reninangiotensin system, plasma bradykinin levels, and BP in normotensive postmenopausal women.
Methods

Subjects
A total of 38 healthy normotensive Japanese postmenopausal women (mean age 55.1 Ϯ 6.9 years, range 47 to 71 years) with no evidence of gynecologic disorders volunteered to participate in this study. Each of the subjects had experienced a natural menopause that had lasted for Ͼ1 year. Menopausal status was confirmed by a serum estradiol (E2) concentration Ͻ20 pg/mL and a serum folliclestimulating hormone (FSH) concentration Ͼ40 mIU/mL. None of the subjects had smoked or received hormonal therapy before enrollment or had any contraindications to such therapy. Before entering the study, each subject underwent physical and laboratory examinations, including a gynecologic evaluation, mammography, 12-lead electrocardiography, and echocardiography. Women with any of the following disorders were excluded: diabetes mellitus, hypertension, thyroid disease, acute or severe chronic liver disease, heart failure, renal failure, thromboembolic or ischemic cardiac disease, breast or endometrial cancer, a personal or family history of breast cancer, or unexplained vaginal bleeding. All of the subjects had a normal BP defined as a systolic BP (SBP) Ͻ140 mm Hg and a diastolic BP (DBP) Ͻ90 mm Hg measured while sitting on at least three different occasions in the outpatient clinic of the Cardiovascular Hospital of Central Japan.
Study Protocol
All patients were randomly assigned to one of two groups: a transdermal HRT group (n ϭ 19) or an oral HRT group (n ϭ 19). The transdermal HRT group was treated with a continuous 17-␤ E2 patch (36 g/day) combined with cyclic oral medroxyprogesterone acetate (MPA) (2.5 mg/ day for 12 days) for 12 months, whereas the oral HRT group was treated with continuous oral conjugated equine estrogen (CEE) (0.625 mg/day) combined with cyclic oral MPA (2.5 mg/day for 12 days) for 12 months. None of the subjects were taking any medication known to influence the renin-angiotensin system or hemodynamic status. Each subject came to the HRT clinic at the Cardiovascular Hospital of Central Japan once per month for a physical checkup, BP, and heart rate measurements; blood samples were also collected before and 12 months after the start of HRT. The blood samples were collected in the morning after the patient had fasted for 12 h and had rested in a supine position for Ͼ30 min. The study protocol was approved by the Ethics Committee of the Cardiovascular Hospital of Central Japan, and written informed consent was obtained from each individual before participation.
Blood was drawn from an anticubital vein into icechilled tubes. The blood samples for the PRA, Ang I, and Ang II assays were collected in chilled glass tubes containing 1 mg of Na 2 -EDTA/mL whole blood. Plasma and serum separated immediately by centrifuging at 3500 rpm for 10 min at 4°C and rapidly frozen and then stored at Ϫ80°C until assayed.
Physical Examination
After collecting the blood samples, the subjects were allowed to rest for at least 30 min before measuring BP and pulse rate. The BP in the subject's right arm was measured three times using a mercury sphygmomanometer, and the mean of the three measurements was recorded. Anthropometric characteristics were then determined. Weight was measured to the nearest 0.1 kg, and height was measured to the nearest 0.5 cm. Body mass index was also calculated.
Assays
Serum total cholesterol, triglyceride, and low-density lipoprotein (LDL) cholesterol concentrations were determined using enzymatic methods (Medca Japan, Konosu, Japan). The serum high-density lipoprotein (HDL) cholesterol concentration was determined electrophoretically using an HDL Cholesterol Supply Kit (Helena Laboratory, Beaumont, TX). Serum FSH and E2 concentrations were measured by radioimmunoassay using commercially available kits (Boehringer Mannheim, Germany). The PRA was determined by radioimmunoassay as previously reported. 4 Both Ang I and Ang II were quantitated by radioimmunoassay according to the original methods devised by SRL, Inc. (Tokyo, Japan). 17 The normal range for Ang I values is Ͻ110 pg/mL, and the normal range for Ang II values is Ͻ22 pg/mL. After mixing the sample with assay buffer (Tris buffer) containing 100 L of tracer ( 125 I-Ang I or Ang II) and 100 L of the primary antibody to Ang I or Ang II, the sample was incubated for 18 to 24 h at 2°to 8°C. A 100-L volume of the secondary antibody was then added, and the mixture was incubated for an additional 1 h at 2°to 8°C. After centrifugation at 3500 rpm for 20 min at 2°to 8°C, the supernatant was decanted and radioactivity was measured. Both Ang I and Ang II levels were determined by extrapolation from standard curves. The plasma bradykinin concentration was measured by a radioimmunoassay, as previously reported. 18 Serum ACE activity was determined by colorimetry according to the method of Kasahara and Ashihara. 19 
Statistical Analysis
Data are reported as mean Ϯ SD. One-way analysis of variance (ANOVA) and the Scheffé F test were used to compare the clinical characteristics of the two groups. Two-way ANOVA for repeated measures was used to analyze the differences between values recorded at baseline and at 12 months. All probability values were twotailed. A value of P Ͻ .05 was considered statistically significant. All statistical analyses were performed using SPSS software, version 11.0 (SPSS Inc., Chicago, IL).
Results
The characteristics of the study population are listed in Table 1 . Before HRT, no significant differences with regard to age, body mass index, total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol were observed between the two groups.
The changes in body mass index, BP, pulse rate, and hormone levels, including FSH, estradiol, renin-angiotensin system, and bradykinin, after 1 year of HRT are listed in Tables 2 and 3 . Body mass index, BP, pulse rate, FSH, estradiol, PRA, ACE activity, Ang I, Ang II, and bradykinin levels at baseline and at 12 months after the start of HRT were similar in the two groups. Body mass index did not change during the study. In the transdermal HRT group, DBP and mean BP were significantly lower after 12 months of HRT (P Ͻ .05), but SBP and pulse rate were not. In the oral HRT group, BP and pulse rate did not change during the study. The HRT was associated with a significant increase in the E2 concentration (P Ͻ .01) and a decrease in the FSH level (P Ͻ .01) in both groups, confirming patient compliance with the regimen. In the transdermal HRT group, the PRA, Ang I, Ang II, and ACE activity levels showed no significant changes, but the bradykinin level decreased (P Ͻ .05). By contrast, at 12 months after the start of HRT, the oral HRT group showed significant increases in PRA, Ang I, Ang II, and bradykinin values (all P Ͻ .01) and a significant decrease in ACE activity (P Ͻ .01).
Discussion
This study was designed to compare the efficacy of transdermally administered E2 and orally administered conjugated equine estrogens on the renin-angiotensin system of normotensive postmenopausal women.
Consistent with the other findings, transdermal HRT did not significantly influence PRA or ACE activity. Seely et al 6 and Faguer de Moustier et al. 7 also demonstrated that transdermal E2 had no effect on PRA in postmenopausal women, and Proudler et al 11 reported no significant changes in PRA or ACE activity as a result of transdermal E2 therapy. In addition, the present study showed that transdermal HRT had no impact on the plasma Ang I or Ang II levels BP ϭ blood pressure; DBP ϭ diastolic blood pressure; FSH ϭ folliclestimulating hormone; HRT ϭ hormone replacement therapy; SBP ϭ systolic blood pressure. All data are shown as mean Ϯ SD.
of normotensive postmenopausal women. These findings may reflect the fact that transdermal HRT did not affect PRA and ACE activity. Despite our results showing that transdermal HRT did not significantly influence the renin-angiotensin system, transdermal HRT did reduce DBP, mean BP, and the plasma bradykinin concentration. Based on the results of 24-h ambulatory BP monitoring, Akkad et al 20 reported significant decreases in night-time SBP and DBP and daytime DBP after transdermal HRT in normotensive postmenopausal women but no significant BP changes after oral HRT. Vongpatanasin et al 21 also reported that transdermal HRT significantly reduced the mean 24-h DBP in normotensive postmenopausal women whereas oral HRT did not. The findings in these studies corroborate the present results. Although the mechanisms by which transdermal HRT decreases BP and plasma bradykinin in postmenopausal women are unclear, several mechanisms have been speculated. Chronic transdermal HRT has been shown to activate the vasodilator process mediated by nitric oxide or prostacyclin and to decrease sympathetic activity in postmenopausal women. 21, 22 This in turn leads to the down-regulation of Ang II type 1 receptor mRNA and tissue ACE activity after the subcutaneous administration of estradiol to ovariectomized rats. 23 The fact that estrogen attenuates Ang type 1 receptor expression in vivo has also been revealed by PET studies. 24 Furthermore, the administration of candesartan to normotensive postmenopausal women receiving HRT decreased plasma bradykinin levels concomitant with a decrease in BP 25 in a recent study of ours. The reduction in BP induced by these vasodilator factors might decrease the bradykinin level as a compensatory effect to normalize the BP.
Oral HRT, on the other hand, increased PRA and serum Ang I and Ang II levels and decreased serum ACE activity without altering BP; these results are compatible with results for oral HRT in several previous studies. 4, 5, 7, 8, 10, 20 The increase in plasma bradykinin concentrations was partly attributable to a decrease in serum ACE activity, which is the same as bradykinin-degrading enzyme (kininase II). In humans, the plasma kallikrein-kinin system generates bradykinin, which is a vasodilator and tissueprotective substance. 26 Of particular interest was the finding that oral HRT increased the plasma concentration of Ang II in postmenopausal women without increasing their BP, despite a reduction in serum ACE activity. Other ACE-independent pathways exist through which Ang II can be produced. Cross talk between bradykinin and angiotensin action, and the opposite effects of the activation of Ang II receptors types 1 and 2 support the hypothesis that the plasma kallikrein-kinin system counterbalances the renin-angiotensin system. 27 This counterbalancing effect between bradykinin and Ang II may contribute to the maintenance of normal BP levels in postmenopausal women receiving oral HRT.
The results of the Heart and Estrogen/progestin Replacement Study (HERS) showed an increased incidence of coronary heart disease during the first year after menopause in women with established coronary disease, 28 and the results of other studies, including the Women's Health Initiative (WHI) study, 29 have confirmed that HRT should not be used for the primary prevention of coronary heart disease. These negative results were found in subjects receiving oral HRT. Thus it seems important to investigate the physiologic effects of estrogen administered by the transdermal route compared with the oral route. In the present study, oral HRT increased plasma Ang II but transdermal HRT did not. The renin-angiotensin system, specifically Ang II, plays a critical role in the pathophysiology of hypertension, cardiac hypertrophy, congestive heart failure, and coronary heart disease. The binding of Ang II to Ang II type-1 receptors produces pathophysiologic effects such as cell growth, nephrosclerosis, vascular media hypertrophy, endothelial damage, neointima formation, and processes leading to atherothrombosis. 30, 31 Because the inhibition of ACE or the blockade of Ang II type-1 receptors improved cardiovascular outcome in a large clinical trial, our results seem to suggest that the neutral effect of transdermal HRT on the renin-angiotensin system might be a safer method of treatment for postmenopausal women. Transdermal HRT decreased DBP and mean BP in normotensive postmenopausal women, whereas oral HRT did not. Even small reductions in DBP in normotensive populations have been postulated to decrease the risk of future coronary heart disease or stroke by 5% to 10%. 32 This indicates that transdermal HRT may be effective for reducing the risk of future cardiovascular disease in normotensive postmenopausal women. Thus large prospective studies are necessary to establish the effect of transdermal HRT on coronary heart disease.
This study has some limitations. Irreversible cryoactivation of prorenin to renin occurs when blood is chilled for centrifugation before freezing. 33 Cryoactivation may have accounted for the relatively large variance in the PRA data. This phenomenon may have obscured differences in the renin level that may have been present in the transdermal group, although the lack of an increase in Ang I and Ang II in the transdermal group may suggest that significant cryoactivation is unlikely to have occurred. Unfortunately renin substrate was not measured in the present study. Renin substrate likely increased in the oral group and may be responsible for the increase in renin system activity.
In conclusion, the results of this study showed that transdermal HRT decreased DBP, mean BP, and the plasma bradykinin concentration in normotensive postmenopausal women without influencing components of the renin-angiotensin system. In contrast oral HRT increased PRA, Ang I, Ang II, and bradykinin, and decreased ACE activity without altering BP. Transdermal HRT, rather than oral HRT, may be beneficial with regard to BP and Ang II levels.
